Learn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment

Simply Wall St.10-23 16:33

Intellia Therapeutics appointed Dr. Jing L. Marantz as Executive Vice President and Chief Medical Officer in October 2026, putting her in charge of translational, development, regulatory and medical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677472029?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-23 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677472029","market":"us","top_or_hot":-1,"title":"Learn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment","media":"Simply Wall St.","content":"<div>\n<p>Intellia Therapeutics appointed Dr. Jing L. Marantz as Executive Vice President and Chief Medical Officer in October 2026, putting her in charge of translational, development, regulatory and medical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Learn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLearn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-23 16:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics appointed Dr. Jing L. Marantz as Executive Vice President and Chief Medical Officer in October 2026, putting her in charge of translational, development, regulatory and medical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul","article_id":"2677472029","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677472029","pubTimestamp":1792744419,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Intellia Therapeutics appointed Dr. Jing L. Marantz as Executive Vice President and Chief Medical Officer in October 2026, putting her in charge of translational, development, regulatory and medical affairs across the pipeline.\nHer track record steering rare disease programs from trials through FDA, EMA and Japanese regulators gives Intellia a leader experienced with complex global approvals and multi-asset portfolios.\nWe will now look at how Intellia Therapeutics's investment narrative...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","BK4585":"ETF&股票定投概念","GXDW":"Global X Dorsey Wright Thematic ETF","BK4556":"基因编辑","RGLO":"Global Equity Active ETF","BK4139":"生物科技","BK4535":"淡马锡持仓","JOYT":"JPMorgan Equity and Options Total Return ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","VGFPF":"Vanguard Funds PLC","BK4588":"碎股","VOTE":"TCW Transform 500 ETF","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","NTLA":"Intellia Therapeutics Inc"},"translate_title":"了解为什么 Intellia Therapeutics 股票的牛市在新 CMO 任命后可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLO":0.64,"VOTE":0.64,"FEBU":0.64,"DECU":0.64,"GXDW":0.64,"NTLA":1.5,"JOYT":0.64,"PMDE":0.64,"VGFPF":0.64},"content_text":"Intellia Therapeutics appointed Dr. Jing L. Marantz as Executive Vice President and Chief Medical Officer in October 2026, putting her in charge of translational, development, regulatory and medical affairs across the pipeline. Her track record steering rare disease programs from trials through FDA, EMA and Japanese regulators gives Intellia a leader experienced with complex global approvals and multi-asset portfolios. We will now look at how Intellia Therapeutics's investment narrative could shift with Dr. Marantz leading clinical and regulatory execution.  Scan 36 healthcare AI stocks that, like Intellia Therapeutics, are leaning on experienced science and clinical leadership to push complex therapies toward real world approval. AdvertisementIntellia Therapeutics Investment Narrative Recap For an investor in Intellia Therapeutics, the core belief is that its CRISPR platform and late stage programs in ATTR amyloidosis and hereditary angioedema can turn strong clinical interest into future approvals and commercial use. The key near term swing factor still sits with those late stage readouts and regulatory milestones. The appointment of Dr. Jing L. Marantz looks additive on execution, but does not change the immediate clinical dependency. The main risk in the next stretch remains concentrated exposure to a couple of lead assets, while the business continues to run at a loss with no product revenue and ongoing cash burn. Dilution over the past year underlines that funding is not a trivial issue. A seasoned Chief Medical Officer may help reduce regulatory and development missteps, although competitive pressure and reimbursement uncertainty around high cost gene editing therapies remain front and center. One data point that feels increasingly relevant alongside this CMO change is management’s own focus on cost control and cash runway, with restructuring efforts already cutting GAAP operating expenses by about 10% year on year and guidance that current resources extend into the first half of 2027. As you think about Intellia Therapeutics, that operational discipline frames how much time the new clinical leader has to drive programs toward key decisions before fresh capital might be needed. Those efficiency moves sit directly next to the catalyst investors are watching, which is faster than expected enrollment in late stage trials, including the expanded 1,200 patient ATTR cardiomyopathy study and strong uptake in hereditary angioedema. Faster recruitment can bring data and regulatory conversations forward. The combination of tighter spending, a defined cash runway and heavy reliance on a few high profile studies means execution quality under Dr. Marantz will be closely watched by anyone weighing the stock’s risk and reward trade off. What The New Clinical Leadership Means For The Numbers For anyone tracking Intellia Therapeutics, the analyst framework around revenue and profit expectations is already laid out in the numbers. Forecasts currently assume revenue growth of 121.3% a year over the next three years, starting from a base where the business is still loss making and investing heavily in development. That backdrop is what Dr. Marantz is stepping into. On the earnings line, analysts are working off current losses of $400.0 million and a scenario where profit margins eventually align with the broader US biotech industry. In that set up, consensus points to potential earnings of $117.5 million by 2029. That shift implies an earnings improvement of about $517.5 million from today’s level, which is a large swing and a reminder of how much operational and clinical execution would need to go right over several years. Valuation work around Intellia Therapeutics ties those assumptions to a future revenue figure of $644.6 million and the same $117.5 million earnings marker in 2029. Analysts then apply a P/E multiple of 41.4x on those projected profits, compared with a current P/E of 4.2x in loss territory and an industry multiple of 17.6x. For you as an investor, the key question is how comfortable you are with that implied step change in revenue growth, profitability and market rating, given the company’s reliance on a handful of late stage programs and a tight cash runway. Intellia Therapeutics' narrative projects $644.6 million revenue and $117.5 million earnings by 2029. This assumes 121.3% yearly revenue growth and an earnings improvement of about $517.5 million from current losses of $400.0 million. Uncover why Intellia Therapeutics' fair value indicates a potential 115% upside to its current price that could narrow quickly. NasdaqGM:NTLA 1-Year Stock Price Chart Exploring Other Perspectives You might read this CMO appointment and focus on execution upside, yet the most cautious analysts worry more about slow commercialization. Before the news, that bearish group was working off revenue of just US$18.6 million and earnings of US$3.3 million by 2029. Those expectations could shift if Intellia Therapeutics updates guidance, so explore both stories. Explore 2 other Intellia Therapeutics fair value estimates, including one that suggests it could be worth just $23.11! Decide For Yourself Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Intellia Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Intellia Therapeutics? If the Intellia Therapeutics story has sharpened your thinking about risk, cash runways and clinical milestones, it can be useful to compare it with other opportunities that match your own goals and tolerance for volatility. The Simply Wall St Screener lets you filter for different profiles so you can line up Intellia Therapeutics against stocks with very different balance sheets, income profiles or share price histories.  If capital preservation ranks high on your list, start with a basket of relatively steady candidates by scanning 30 resilient stocks with low risk scores that aim to keep drawdowns in check while still offering equity exposure. If your focus is on quality at a reasonable price, look through a curated 29 high quality undervalued stocks where stronger fundamentals and lower implied valuations sit side by side. If you want fresh ideas that are not already crowded, broaden your watchlist by reviewing a 20 high quality undiscovered gems that filters for solid financials in companies that are still under the radar.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677472029","isCrawlerRequest":true}